Salmon Arm city councillors raised concerns about who would pay for a sewer main extension in Canoe when discussing a ...

The drinks trolley is on wheels, featuring navy and gold accents and mirrored sections with sensor battery lighting, creating ...

All ratings are determined solely by our editorial team. When you put your dough into a one-year Bread Savings CD, you’ll earn a very competitive 4.30% APY, which is compounded daily so your ...

For the past couple of years, investors have watched CD rates climb to levels not seen in decades. However, with the Federal Reserve cutting the federal funds rate by a half-point in September ...

Note that the Chase CD relationship rates in the above table span all three balance tiers: $1,000 to $9,999.99, $10,000 to $99,999.99, and $100,000 or more. Here are our reviews on other popular ...

The bank offers high APYs on some short-term CDs, but they come with a steep deposit requirement FG Trade / Getty Images Wells Fargo offers a limited number of CD terms with high minimum deposit ...

The best 10-year CD rates may also be higher than some people realize, especially when it comes to highly competitive institutions and CDs purchased in larger amounts (called jumbo CDs).

Barclays CD rates range from 0.10% to 4.50% APY. Barclays doesn’t charge fees or require a minimum deposit amount for its CDs. You can choose from nine CD term options, with durations ranging ...

(Bloomberg) -- Clayton Dubilier & Rice is nearing a deal to acquire Sanofi’s consumer health unit for about €15 billion ... Representatives for CD&R and PAI Partners declined to comment.

(Reuters) -Sanofi is closing in on a deal to sell its consumer health unit for about 15 billion euros ($16.4 billion) to U.S. private equity firm Clayton Dubilier & Rice (CD&R), a person familiar ...

Clayton Dubilier & Rice is nearing a deal to acquire Sanofi’s consumer health unit for about €15 billion ($16.4 billion), in what would be one of the largest European transactions this year ...

In September, Bloomberg reported that Sanofi had received two separate bids from CD&R and rival PAI Partners for the Opella unit. CD&R has kept away interest from rival PAI Partners for the unit ...